Remove the second chin with one injection?

In Europe, they will test a medicine against double chin
Copper newsThe dermatological division of the German pharmaceutical giant Bayer HealthCare called Intendis and the American cosmetology pharmaceutical company Kythera Biopharmaceuticals have announced the start of Phase III clinical trials of a new drug for removing double chin, according to the Bayer website (First Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction of Submental Fat).

The injection drug, sodium deoxycholate, codenamed ATX-101, was developed for the treatment of lipomas, benign tumors from subcutaneous adipose tissue, as well as other undesirable fatty growths, such as double chin. This substance, which is a salt of one of the bile acids, emulsifies fats, dissolving their excess deposits.

To date, ATX-101 has successfully passed two Phase I studies and three Phase II studies. They showed that the drug has a high selectivity against fat cells and is quickly excreted from the body. Its injections into adipose tissue are able to reduce the volume of fat deposits without significant side effects.

Two multicenter, randomized, double-blind, placebo-controlled phase III trials involving approximately 720 patients in 64 medical centers in the UK, France, Germany, Belgium, Spain and Italy have now been initiated in Europe. They are designed to determine the effectiveness and safety of using ATX-101 to reduce the second chin.

The results will be evaluated both objectively (by the degree of fat reduction) and subjectively (by patients' satisfaction with the cosmetic effect). If successful, companies will be able to apply for permission to use the drug for this indication.

According to Intendis and Kythera Executive Directors Marc Lafeuille and Keith Leonard, both companies are satisfied with the cooperation and have high hopes for the ATX-101.

Portal "Eternal youth" http://vechnayamolodost.ru
14.01.2011